These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32214521)

  • 1. Spontaneous Ejaculation Induced with Atomoxetine.
    Yaylacı F; Şahbudak B; Küçük Ö
    Psychopharmacol Bull; 2020 Mar; 50(1):40-43. PubMed ID: 32214521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
    Gaillez C; Sorbara F; Perrin E
    Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
    Christman AK; Fermo JD; Markowitz JS
    Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.
    Svanborg P; Thernlund G; Gustafsson PA; Hägglöf B; Poole L; Kadesjö B
    Eur Child Adolesc Psychiatry; 2009 Apr; 18(4):240-9. PubMed ID: 19156355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
    Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
    Hong J; Dilla T; Arellano J
    BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.
    Caballero J; Nahata MC
    Clin Ther; 2003 Dec; 25(12):3065-83. PubMed ID: 14749146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation Syndrome in a Patient With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine: A Case Report.
    Karakaya SEK; Yektaş Ç; Tufan AE
    Clin Neuropharmacol; 2021 May-Jun 01; 44(3):101-103. PubMed ID: 33661138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current issues around the pharmacotherapy of ADHD in children and adults.
    Meijer WM; Faber A; van den Ban E; Tobi H
    Pharm World Sci; 2009 Oct; 31(5):509-516. PubMed ID: 19562500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
    Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
    J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.
    Brown TE
    J Child Adolesc Psychopharmacol; 2004; 14(1):129-36. PubMed ID: 15142400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
    McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
    BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.